• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is GH Research (GHRS) Fully Valued Following Its Share Price Surge?

    Simply Wall St·08/01/2026 18:19:35
    语音播报

    GH Research (NasdaqGM:GHRS) has drawn attention after recent share price moves, with the stock last closing at $28.07. Investors are weighing clinical progress in depression treatments against ongoing losses and early stage revenue.

    See our latest analysis for GH Research.

    For context, GH Research has shown strong momentum over longer periods, with a 35.54% 90 day share price return and a 104.29% 1 year total shareholder return that reflects shifting expectations around its depression treatment pipeline and risk profile.

    If you are comparing GH Research with other high growth stories in healthcare, this is a good moment to widen the search and review the 41 healthcare AI stocks

    After a sharp move and with no current revenue in place, GH Research now sits at a level where some investors may feel pressure to act quickly. Is it worth stepping in today, or waiting for a clearer entry after evaluating valuation next?

    Preferred Price to Book Multiple of 7.3x: Is it justified?

    On a simple yardstick, GH Research looks expensive next to its peers. The stock trades at a P/B multiple of 7.3x, while both the US pharmaceuticals industry and its closer peer group sit at lower levels based on the latest data.

    P/B compares the company’s market value to its net assets on the balance sheet. For a clinical stage biopharmaceutical company with no current revenue and ongoing losses, a higher P/B often reflects how much investors are willing to pay today for the possibility of future products, rather than what is already on the books.

    Here, GH Research is priced well above both comparison points. The current 7.3x P/B is higher than the US pharmaceuticals industry average of 2.4x and also above the peer average of 4.4x. That gap suggests investors are currently assigning a richer valuation to GH Research than to many similar companies, even though it is unprofitable and forecast to remain so for at least the next three years.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-book of 7.3x (OVERVALUED)

    However, GH Research still carries clear risks, including its lack of current revenue, ongoing losses of $56.413m, and reliance on successful clinical trial outcomes.

    Find out about the key risks to this GH Research narrative.

    Next Steps

    If this all feels finely balanced, it may be sensible to act quickly and review the underlying metrics yourself before the story moves on. To assess how those risks stack up for GH Research, start with the 2 important warning signs

    Looking for more GH Research investment ideas?

    If GH Research has sparked your interest, do not stop here. Broaden your watchlist now so you are not relying on a single high risk story.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.